# Viemed Healthcare, Inc.: overview

VMD · Nasdaq · CIK 1729149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vmd.md) · [Financials](/companies/vmd/financials.md) · [Filings](/companies/vmd/filings.md) · [Insiders](/companies/vmd/insiders.md)

Latest reported revenue: [$78.1m](/filings/0001729149-26-000042.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:Revenues, accession 0001729149-26-000042).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [58.0](/filings/0001729149-25-000149.md) | [60.7 d](/filings/0001729149-26-000009.md) | [59.1](/filings/0001729149-26-000029.md) | [63.1](/filings/0001729149-26-000042.md) | [71.9](/filings/0001729149-25-000149.md) | [76.2 d](/filings/0001729149-26-000009.md) | [75.4](/filings/0001729149-26-000029.md) | [78.1](/filings/0001729149-26-000042.md) |
| Gross margin | % | [59.3%](/filings/0001729149-25-000149.md) | [59.5% d](/filings/0001729149-26-000009.md) | [56.3%](/filings/0001729149-26-000029.md) | [58.3%](/filings/0001729149-26-000042.md) | [57.5%](/filings/0001729149-25-000149.md) | [57.9% d](/filings/0001729149-26-000009.md) | [56.8%](/filings/0001729149-26-000029.md) | [57.7%](/filings/0001729149-26-000042.md) |
| Operating margin | % | [9.7%](/filings/0001729149-25-000149.md) | [10.6% d](/filings/0001729149-26-000009.md) | [6.5%](/filings/0001729149-26-000029.md) | [8.1%](/filings/0001729149-26-000042.md) | [7.8%](/filings/0001729149-25-000149.md) | [11.0% d](/filings/0001729149-26-000009.md) | [5.7%](/filings/0001729149-26-000029.md) | [5.7%](/filings/0001729149-26-000042.md) |
| Net margin | % | [6.7%](/filings/0001729149-25-000149.md) | [7.1% d](/filings/0001729149-26-000009.md) | [4.4%](/filings/0001729149-26-000029.md) | [5.0%](/filings/0001729149-26-000042.md) | [4.9%](/filings/0001729149-25-000149.md) | [7.4% d](/filings/0001729149-26-000009.md) | [3.4%](/filings/0001729149-26-000029.md) | [3.5%](/filings/0001729149-26-000042.md) |
| Diluted EPS | $ per share | [0.10](/filings/0001729149-25-000149.md) | not reported | [0.06](/filings/0001729149-26-000029.md) | [0.08](/filings/0001729149-26-000042.md) | [0.09](/filings/0001729149-25-000149.md) | not reported | [0.06](/filings/0001729149-26-000029.md) | [0.07](/filings/0001729149-26-000042.md) |
| Free cash flow | $m | [1.7 d](/filings/0001729149-25-000149.md) | [3.2 d](/filings/0001729149-26-000009.md) | [(12.6)](/filings/0001729149-26-000029.md) | [4.1 d](/filings/0001729149-26-000042.md) | [10.7 d](/filings/0001729149-25-000149.md) | [9.7 d](/filings/0001729149-26-000009.md) | [1.4](/filings/0001729149-26-000029.md) | [7.4 d](/filings/0001729149-26-000042.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [117](/filings/0001729149-23-000040.md) | [139](/filings/0001729149-25-000056.md) | [183](/filings/0001729149-26-000009.md) | [224](/filings/0001729149-26-000009.md) | [270](/filings/0001729149-26-000009.md) |
| Gross margin | % | [62.7%](/filings/0001729149-23-000040.md) | [61.0%](/filings/0001729149-25-000056.md) | [61.6%](/filings/0001729149-26-000009.md) | [59.4%](/filings/0001729149-26-000009.md) | [57.5%](/filings/0001729149-26-000009.md) |
| Operating margin | % | [9.9%](/filings/0001729149-23-000040.md) | [5.9%](/filings/0001729149-25-000056.md) | [7.8%](/filings/0001729149-26-000009.md) | [8.0%](/filings/0001729149-26-000009.md) | [8.5%](/filings/0001729149-26-000009.md) |
| Net margin | % | [7.8%](/filings/0001729149-23-000040.md) | [4.5%](/filings/0001729149-25-000056.md) | [5.6%](/filings/0001729149-26-000009.md) | [5.0%](/filings/0001729149-26-000009.md) | [5.5%](/filings/0001729149-26-000009.md) |
| Diluted EPS | $ per share | [0.22](/filings/0001729149-23-000040.md) | [0.16](/filings/0001729149-25-000056.md) | [0.25](/filings/0001729149-26-000009.md) | [0.28](/filings/0001729149-26-000009.md) | [0.37](/filings/0001729149-26-000009.md) |
| Free cash flow | $m | [2.8](/filings/0001729149-23-000040.md) | [4.9](/filings/0001729149-25-000056.md) | [19.1](/filings/0001729149-26-000009.md) | [1.3](/filings/0001729149-26-000009.md) | [11.9](/filings/0001729149-26-000009.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vmd/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $54.6m | 4,788,307 |  | Added +165,745 |
| [Forager Capital Management, LLC](/funds/1802986.md) | 2026-06-30 | $24.4m | 2,141,184 |  | Reduced −684,687 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $15.1m | 1,321,676 |  | Added +18,292 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $13.9m | 1,222,534 |  | Reduced −199,100 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $11.5m | 1,006,195 |  | Added +107,876 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $11.1m | 973,744 |  | Added +194,222 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $9.0m | 786,269 |  | Added +75,083 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $8.7m | 762,097 |  | Added +19,138 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $7.2m | 632,445 |  | Reduced −251,338 |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $7.2m | 632,445 |  | Reduced −251,338 |

## Recent filings

[All 414 filings](/companies/vmd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-24 | 17:22 ET | [SCHEDULE 13D/A](/filings/0001781905-26-000019.md) | Ownership report, active investor, amended | 0001781905-26-000019 |
| 2026-08-20 | 17:03 ET | [8-K](/filings/0001729149-26-000048.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001729149-26-000048 |
| 2026-08-03 | 17:04 ET | [10-Q](/filings/0001729149-26-000042.md) | Quarterly report, period 2026-06-30 | 0001729149-26-000042 |
| 2026-08-03 | 17:01 ET | [8-K](/filings/0001729149-26-000041.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001729149-26-000041 |
| 2026-06-04 | 16:07 ET | [8-K](/filings/0001729149-26-000034.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001729149-26-000034 |
| 2026-06-02 | 17:00 ET | [8-K](/filings/0001729149-26-000032.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001729149-26-000032 |
| 2026-05-05 | 17:02 ET | [10-Q](/filings/0001729149-26-000029.md) | Quarterly report, period 2026-03-31 | 0001729149-26-000029 |
| 2026-05-05 | 17:00 ET | [8-K](/filings/0001729149-26-000028.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001729149-26-000028 |
| 2026-04-22 | 16:45 ET | [DEF 14A](/filings/0001729149-26-000022.md) | Proxy statement, period 2026-04-22 | 0001729149-26-000022 |
| 2026-03-16 | 16:51 ET | [8-K](/filings/0001729149-26-000011.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001729149-26-000011 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001729149-26-000009.md), filed Mar 4, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/614c2347-ea55-4567-aa60-628dcffe2532)

## About the filer

- CIK: 1729149
- Tickers: VMD
- Exchange: Nasdaq
- SIC code: 8090 Services-Misc Health & Allied Services, NEC
- State of incorporation: A1
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.